A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors

Background and Objectives Immune checkpoint inhibitors (ICIs) are effective in various types of cancer and cause immune-related adverse events (irAEs). The occurrence of irAEs is associated with improved survival outcome. We investigated the association between the occurrence of irAEs and overall su...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Hiroki Hata MS, Chikako Matsumura PhD, Yugo Chisaki PhD, Kae Nishioka, Misaki Tokuda, Kazuyo Miyagi, Tomoki Suizu MS, Yoshitaka Yano PhD
Μορφή:	Άρθρο
Γλώσσα:	English
Έκδοση:	SAGE Publishing 2022-09-01
Σειρά:	Cancer Control
Διαθέσιμο Online:	https://doi.org/10.1177/10732748221130576

Παρόμοια τεκμήρια

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
ανά: Hiroki Hata MS, κ.ά.
Έκδοση: (2020-12-01)

Myocardial Vasculitis Associated With the Immune Checkpoint Inhibitor Pembrolizumab
ανά: Hideo Oishi, MD, κ.ά.
Έκδοση: (2020-10-01)

Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
ανά: Arthur E. Frankel MD, κ.ά.
Έκδοση: (2019-04-01)

Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
ανά: Taichi Miyawaki, MD, κ.ά.
Έκδοση: (2020-06-01)

Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosisCentral MessagePerspective
ανά: Bilguun Erkhem-Ochir, MD, κ.ά.
Έκδοση: (2021-03-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
ανά: Samit Chatterjee PhD, κ.ά.
Έκδοση: (2017-07-01)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
ανά: Tara Davidson, MD, κ.ά.
Έκδοση: (2022-07-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
ανά: Chenxing Zhang, PhD, κ.ά.
Έκδοση: (2020-03-01)

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
ανά: Daisuke Hazama, MD, PhD, κ.ά.
Έκδοση: (2024-01-01)

A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related MyocarditisNovel Teaching Points
ανά: Tatsuya Nishikawa, MD, PhD, κ.ά.
Έκδοση: (2022-07-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
ανά: Kenji Morimoto, MD, PhD, κ.ά.
Έκδοση: (2022-09-01)

Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors
ανά: Mariana Mirabel, MD, PhD, κ.ά.
Έκδοση: (2020-09-01)

A Modified Method for the Quantification of Immune Checkpoint Ligands on Exosomes from Human Serum using Flow Cytometry
ανά: Alan Guillermo Alejandre Gonzalez PhD, κ.ά.
Έκδοση: (2023-05-01)

A Common Pituitary Autoantibody in Two Patients with Immune Checkpoint Inhibitor-Mediated Hypophysitis: ZCCHC8
ανά: Amanda Leiter, MD, MSCR, κ.ά.
Έκδοση: (2020-07-01)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
ανά: Yasunori Murata, MD, PhD, κ.ά.
Έκδοση: (2023-12-01)

The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study
ανά: Fatih Kus MD, κ.ά.
Έκδοση: (2024-09-01)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
ανά: Shiting Xu, MD, κ.ά.
Έκδοση: (2022-04-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
ανά: Yuto Terashima, MD, κ.ά.
Έκδοση: (2023-11-01)

Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma
ανά: Xinlun Dai MD, κ.ά.
Έκδοση: (2020-08-01)

Immune Checkpoint Inhibitor Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis
ανά: Lianghui Zhang MS, κ.ά.
Έκδοση: (2024-08-01)

A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis
ανά: Mahdieh Azizi, PhD, κ.ά.
Έκδοση: (2024-01-01)

Identification of Novel Cuproptosis-Related Genes Mediating the Prognosis and Immune Microenvironment in Cholangiocarcinoma
ανά: Qiang Liu PhD, κ.ά.
Έκδοση: (2024-04-01)

Comprehensive Characterization of Cardiac, Skeletal and Diaphragmatic Myotoxicity Using CMR in Patients with Immune Checkpoint Inhibitor Therapy and Relation to Outcomes
ανά: Etienne Charpentier, MD, κ.ά.
Έκδοση: (2024-01-01)

Dosimetric Modeling of Lymphopenia in Patients With Metastatic Cancer Receiving Palliative Radiation and PD-1 Immune Checkpoint Inhibitors
ανά: Jack M. Qian, MD, κ.ά.
Έκδοση: (2022-03-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
ανά: Mandy Jongbloed, MD, κ.ά.
Έκδοση: (2025-03-01)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors∗
ανά: Dorothy M. Gujral, PhD, κ.ά.
Έκδοση: (2020-02-01)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
ανά: Ying Teng PhD, κ.ά.
Έκδοση: (2022-03-01)

IgA pemphigus as an immune checkpoint inhibitor-associated skin manifestation
ανά: Tristan V.M. Bruijn, MD, κ.ά.
Έκδοση: (2024-05-01)

Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
ανά: Kana Hashimoto, MD, κ.ά.
Έκδοση: (2024-11-01)

IL-23 inhibitor treatment of immune checkpoint inhibitor-associated psoriasis: Case series and review of literature
ανά: Natalie Bourand, MS, κ.ά.
Έκδοση: (2025-02-01)

Inhibits Murine Leukemia WEHI-3 Cells and Promotes Immune Response In Vivo
ανά: Hsin-Ling Yang PhD, κ.ά.
Έκδοση: (2017-09-01)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
ανά: Roger Y. Kim, MD, κ.ά.
Έκδοση: (2021-06-01)

Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review
ανά: Benjamin M.P. Elyan, MBChB, κ.ά.
Έκδοση: (2023-07-01)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
ανά: Marco Tagliamento, MD, κ.ά.
Έκδοση: (2023-01-01)

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology
ανά: Denis L. Jardim MD, PhD, κ.ά.
Έκδοση: (2018-12-01)

Seeking “protective” and “harmful” immune genes during chronic HIV-1 infection by transcriptome analysis
ανά: Lingyan Zhu, PhD, κ.ά.
Έκδοση: (2018-09-01)

Immune Checkpoint Inhibitors for the Therapy of Thymoma
ανά: Alicia Quilez, MD, κ.ά.
Έκδοση: (2020-03-01)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation
ανά: Jia-Jun Wu, MD, κ.ά.
Έκδοση: (2022-06-01)

The Value of Combined Detection of Megakaryocyte and Platelet Parameters for the Diagnosis of Primary Immune Thrombocytopenia
ανά: Weiwei Wang MS, κ.ά.
Έκδοση: (2022-08-01)

Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
ανά: Sakeena Fatima, BA, κ.ά.
Έκδοση: (2018-04-01)